The “potential” caseload for use of novel surgical sealants, glues, hemostasis and anti-adhesion products is rapidly becoming “actual” caseload. Nonetheless, there is remarkable staying power in surgical technologies for traditional technologies (e.g., sutures, staples). Consequently, the caseload currently addressed by sutures, staples and clips remains resistant, though eroding, toward penetration by novel wound technologies.
Specific applications of novel wound sealing, hemostasis and closure technologies include the following:
- Local hemostatic measures for both surgical and trauma cases
- Surgery in patients with bleeding disorders (e.g., hemophilia, severe thrombocytopenia) and non-bleeding cases with suspected fluid oozing
- Surgery in nonsuturable organs (e.g., brain, liver, lung, pancreas, thymus) or to repair unhealthy tissue (e.g., irradiated bowel or tissue of elderly patients)
- Cardiovascular, microvascular surgery and vascular grafts (e.g., aneurysm repair, coronary bypass, etc.)
- Nerve grafts
- Skin grafts, particularly plastic surgery
- Surgery of small or difficult to reach organs (e.g., tympanoplasty, ENT, eye)
- Sealing of body cavities, fistulae, pneumothorax, cranium, etc.
- Anastomosis of gastrointestinal, tract and other ductal organs
At the aggregate level, the potential for novel products in the hemostasis, sealing, closure and anti-adhesion of wounds is distributed across the following clinical areas by caseload distribution in the U.S., Europe, and Rest of World:
Source: MedMarket Diligence, LLC; February 2012 report #S190, “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2010-2017.” (This report is available for immediate download.)